Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masatoshi Abe

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Dermatology and Therapy|June 11, 2022
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm StudyYukari Okubo, Hidetoshi Takahashi, Ryosuke Hino, et al.
Bioorganic & Medicinal Chemistry Letters|March 25, 2009
Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitorsTakumi Watanabe, Isao Momose, Masatoshi Abe, et al.
Journal of Tissue Viability|November 29, 2020
Validity of skin blot examination for albumin and nerve growth factor β to detect itching of the skin in Indonesian older adultsDianis Wulan Sari, Takeo Minematsu, Mikako Yoshida, et al.
The Journal of Dermatology|October 31, 2014
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 studyMamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, et al.
The Journal of Dermatology|May 10, 2025
Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance StudyMamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
The Journal of Dermatology|May 3, 2005
Cholesterol crystal embolization: skin manifestation, gastrointestinal and central nervous symptom treated with corticosteroidSei-ichiro Motegi, Masatoshi Abe, Akira Shimizu, et al.
Dermatology and Therapy|August 11, 2025
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 StudyYukari Okubo, Yayoi Tada, Hidetoshi Takahashi, et al.
The Journal of Dermatology|July 27, 2025
Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With BiologicsKoji Kamiya, Yukari Okubo, Yayoi Tada, et al.
Dermatology and Therapy|March 23, 2025
Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching-A Japanese e-Delphi SurveyYayoi Tada, Shinichi Imafuku, Kazumitsu Sugiura, et al.
The Journal of Dermatology|May 22, 2024
Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance studyMamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Dermatology and Therapy|June 11, 2022
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm StudyYukari Okubo, Hidetoshi Takahashi, Ryosuke Hino, et al.
Bioorganic & Medicinal Chemistry Letters|March 25, 2009
Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitorsTakumi Watanabe, Isao Momose, Masatoshi Abe, et al.
Journal of Tissue Viability|November 29, 2020
Validity of skin blot examination for albumin and nerve growth factor β to detect itching of the skin in Indonesian older adultsDianis Wulan Sari, Takeo Minematsu, Mikako Yoshida, et al.
The Journal of Dermatology|October 31, 2014
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 studyMamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, et al.
The Journal of Dermatology|May 10, 2025
Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance StudyMamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
The Journal of Dermatology|May 3, 2005
Cholesterol crystal embolization: skin manifestation, gastrointestinal and central nervous symptom treated with corticosteroidSei-ichiro Motegi, Masatoshi Abe, Akira Shimizu, et al.
Dermatology and Therapy|August 11, 2025
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 StudyYukari Okubo, Yayoi Tada, Hidetoshi Takahashi, et al.
The Journal of Dermatology|July 27, 2025
Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With BiologicsKoji Kamiya, Yukari Okubo, Yayoi Tada, et al.
Dermatology and Therapy|March 23, 2025
Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching-A Japanese e-Delphi SurveyYayoi Tada, Shinichi Imafuku, Kazumitsu Sugiura, et al.
The Journal of Dermatology|May 22, 2024
Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance studyMamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, et al.
Pageof 10